Skip to main content

S&P 500 —

Nasdaq-100 —

Dow —

Nasdaq · Common stock

Neurocrine Biosciences (NBIX)

$145.87 +$3.17 (+2.22%)

Day’s range
$142.34–$146.00
Volume
1.3M

NBIX price history

NBIX closed at $145.87 on Oct. 26, 2026. Over the past year, its daily close ranged from $123.10 on Feb. 12, 2026 to $185.50 on July 30, 2026.

Source: third-party providers. Daily closing prices, adjusted for stock splits; dividends not included. The price scale runs from $120 to $200, not from zero.
Data table: NBIX daily closes, the past year
NBIX daily closing prices, Oct. 27, 2025 to Oct. 26, 2026, newest first
DateClose
Oct. 26, 2026$145.87
Oct. 23, 2026$142.70
Oct. 22, 2026$143.29
Oct. 21, 2026$141.31
Oct. 20, 2026$142.00
Oct. 19, 2026$136.98
Oct. 16, 2026$135.71
Oct. 15, 2026$136.95
Oct. 14, 2026$135.91
Oct. 13, 2026$135.13
Oct. 12, 2026$141.37
Oct. 9, 2026$142.44
Oct. 8, 2026$141.25
Oct. 7, 2026$143.47
Oct. 6, 2026$145.51
Oct. 5, 2026$144.21
Oct. 2, 2026$143.18
Oct. 1, 2026$140.71
Sept. 30, 2026$141.84
Sept. 29, 2026$138.35
Sept. 28, 2026$140.44
Sept. 25, 2026$138.40
Sept. 24, 2026$138.94
Sept. 23, 2026$139.49
Sept. 22, 2026$142.25
Sept. 21, 2026$143.96
Sept. 18, 2026$146.23
Sept. 17, 2026$151.83
Sept. 16, 2026$149.50
Sept. 15, 2026$150.02
Sept. 14, 2026$157.22
Sept. 11, 2026$156.22
Sept. 10, 2026$156.57
Sept. 9, 2026$155.14
Sept. 8, 2026$155.13
Sept. 4, 2026$155.64
Sept. 3, 2026$158.35
Sept. 2, 2026$157.79
Sept. 1, 2026$156.76
Aug. 31, 2026$154.03
Aug. 28, 2026$154.06
Aug. 27, 2026$155.92
Aug. 26, 2026$156.59
Aug. 25, 2026$153.37
Aug. 24, 2026$153.04
Aug. 21, 2026$152.57
Aug. 20, 2026$152.93
Aug. 19, 2026$155.54
Aug. 18, 2026$154.23
Aug. 17, 2026$154.49
Aug. 14, 2026$152.72
Aug. 13, 2026$150.82
Aug. 12, 2026$156.49
Aug. 11, 2026$161.94
Aug. 10, 2026$164.92
Aug. 7, 2026$163.41
Aug. 6, 2026$159.82
Aug. 5, 2026$161.50
Aug. 4, 2026$166.06
Aug. 3, 2026$166.23
July 31, 2026$166.80
July 30, 2026$185.50
July 29, 2026$180.79
July 28, 2026$182.83
July 27, 2026$176.41
July 24, 2026$175.77
July 23, 2026$174.15
July 22, 2026$172.69
July 21, 2026$179.05
July 20, 2026$173.00
July 17, 2026$170.88
July 16, 2026$171.55
July 15, 2026$172.05
July 14, 2026$172.04
July 13, 2026$174.10
July 10, 2026$177.11
July 9, 2026$180.55
July 8, 2026$178.24
July 7, 2026$177.49
July 6, 2026$174.10
July 2, 2026$174.26
July 1, 2026$167.77
June 30, 2026$168.54
June 29, 2026$170.00
June 26, 2026$168.52
June 25, 2026$164.18
June 24, 2026$166.06
June 23, 2026$161.44
June 22, 2026$161.62
June 18, 2026$158.29
June 17, 2026$159.00
June 16, 2026$156.42
June 15, 2026$159.51
June 12, 2026$159.76
June 11, 2026$162.71
June 10, 2026$160.86
June 9, 2026$165.24
June 8, 2026$163.12
June 5, 2026$163.88
June 4, 2026$167.35
June 3, 2026$165.11
June 2, 2026$154.84
June 1, 2026$161.00
May 29, 2026$158.30
May 28, 2026$156.39
May 27, 2026$155.83
May 26, 2026$155.73
May 22, 2026$156.70
May 21, 2026$155.50
May 20, 2026$154.67
May 19, 2026$154.36
May 18, 2026$157.21
May 15, 2026$158.42
May 14, 2026$159.05
May 13, 2026$161.32
May 12, 2026$155.80
May 11, 2026$150.59
May 8, 2026$152.25
May 7, 2026$149.59
May 6, 2026$147.02
May 5, 2026$135.06
May 4, 2026$134.07
May 1, 2026$131.78
April 30, 2026$131.67
April 29, 2026$131.23
April 28, 2026$128.12
April 27, 2026$128.04
April 24, 2026$127.68
April 23, 2026$130.19
April 22, 2026$131.18
April 21, 2026$130.22
April 20, 2026$131.59
April 17, 2026$133.25
April 16, 2026$128.41
April 15, 2026$131.44
April 14, 2026$130.81
April 13, 2026$126.32
April 10, 2026$128.89
April 9, 2026$131.64
April 8, 2026$133.15
April 7, 2026$130.90
April 6, 2026$132.48
April 2, 2026$131.60
April 1, 2026$132.56
March 31, 2026$131.74
March 30, 2026$128.72
March 27, 2026$128.32
March 26, 2026$132.42
March 25, 2026$131.13
March 24, 2026$127.86
March 23, 2026$127.05
March 20, 2026$127.68
March 19, 2026$129.70
March 18, 2026$130.71
March 17, 2026$130.71
March 16, 2026$129.85
March 13, 2026$129.78
March 12, 2026$127.78
March 11, 2026$129.54
March 10, 2026$129.86
March 9, 2026$129.93
March 6, 2026$128.13
March 5, 2026$129.64
March 4, 2026$133.44
March 3, 2026$131.14
March 2, 2026$132.38
Feb. 27, 2026$132.25
Feb. 26, 2026$130.64
Feb. 25, 2026$131.15
Feb. 24, 2026$130.96
Feb. 23, 2026$128.38
Feb. 20, 2026$128.63
Feb. 19, 2026$130.10
Feb. 18, 2026$128.38
Feb. 17, 2026$127.76
Feb. 13, 2026$124.12
Feb. 12, 2026$123.10
Feb. 11, 2026$137.44
Feb. 10, 2026$137.65
Feb. 9, 2026$139.56
Feb. 6, 2026$141.20
Feb. 5, 2026$137.93
Feb. 4, 2026$137.86
Feb. 3, 2026$138.98
Feb. 2, 2026$137.63
Jan. 30, 2026$136.06
Jan. 29, 2026$137.96
Jan. 28, 2026$134.66
Jan. 27, 2026$133.89
Jan. 26, 2026$134.51
Jan. 23, 2026$136.18
Jan. 22, 2026$137.37
Jan. 21, 2026$135.41
Jan. 20, 2026$134.54
Jan. 16, 2026$132.39
Jan. 15, 2026$133.35
Jan. 14, 2026$135.33
Jan. 13, 2026$132.26
Jan. 12, 2026$132.66
Jan. 9, 2026$135.79
Jan. 8, 2026$135.57
Jan. 7, 2026$140.62
Jan. 6, 2026$137.35
Jan. 5, 2026$135.99
Jan. 2, 2026$140.60
Dec. 31, 2025$141.83
Dec. 30, 2025$140.95
Dec. 29, 2025$143.64
Dec. 26, 2025$145.26
Dec. 24, 2025$146.93
Dec. 23, 2025$147.28
Dec. 22, 2025$147.53
Dec. 19, 2025$145.00
Dec. 18, 2025$141.84
Dec. 17, 2025$141.70
Dec. 16, 2025$148.74
Dec. 15, 2025$154.06
Dec. 12, 2025$152.80
Dec. 11, 2025$154.75
Dec. 10, 2025$155.63
Dec. 9, 2025$155.02
Dec. 8, 2025$154.99
Dec. 5, 2025$155.51
Dec. 4, 2025$154.22
Dec. 3, 2025$151.96
Dec. 2, 2025$152.48
Dec. 1, 2025$150.88
Nov. 28, 2025$152.16
Nov. 26, 2025$151.58
Nov. 25, 2025$143.53
Nov. 24, 2025$141.25
Nov. 21, 2025$141.83
Nov. 20, 2025$138.98
Nov. 19, 2025$138.06
Nov. 18, 2025$138.63
Nov. 17, 2025$143.56
Nov. 14, 2025$144.86
Nov. 13, 2025$144.17
Nov. 12, 2025$146.85
Nov. 11, 2025$147.29
Nov. 10, 2025$150.02
Nov. 7, 2025$152.37
Nov. 6, 2025$154.80
Nov. 5, 2025$153.75
Nov. 4, 2025$143.19
Nov. 3, 2025$141.96
Oct. 31, 2025$143.21
Oct. 30, 2025$138.04
Oct. 29, 2025$138.02
Oct. 28, 2025$147.38
Oct. 27, 2025$148.94

Key figures

52-week range
$123.10–$185.50Low Feb. 12, 2026; high July 30, 2026
Average daily volume
1.3MPast 3 months
Market value
$14.83B
Dividend yield
—
From 52-week high
−21.36%

Price change

1 month
+5.40%
3 months
−17.01%
Year to date
+2.85%
1 year
+1.30%

$1,000 a year ago

$1,000 put into NBIX at the close on Oct. 24, 2025 would be worth $1,013.

Price only, dividends not included.

What Wall Street says about NBIX

In the past 90 days, Wall Street firms published 20 rating or price-target actions on NBIX: 1 new rating, 2 reiterated ratings, 14 raised price targets and 3 lowered price targets.

Rating and price-target actions on NBIX, past 90 days
ActionRating
NeedhamReiteratesBuy$204
BMO CapitalCuts targetMarket perform$164 to $150
GuggenheimAssumes coverageBuy$207
UBSCuts targetBuy$231 to $214
Morgan StanleyRaises targetEqual-weight$182 to $183
RBC CapitalReiteratesOutperform$198
CitigroupRaises targetBuy$249 to $253
Morgan StanleyCuts targetEqual-weight$196 to $182
Canaccord GenuityRaises targetBuy$200 to $210
Truist SecuritiesRaises targetBuy$200 to $213
WedbushRaises targetOutperform$185 to $194
Cantor FitzgeraldRaises targetOverweight$210 to $215
CitigroupRaises targetBuy$246 to $249
GuggenheimRaises targetBuy$200 to $222
Morgan StanleyRaises targetEqual-weight$193 to $196
NeedhamRaises targetBuy$200 to $204
Piper SandlerRaises targetOverweight$207 to $210
RBC CapitalRaises targetOutperform$195 to $198
StifelRaises targetBuy$188 to $215
TD CowenRaises targetBuy$200 to $220

Ratings and price targets are the firms’ own opinions, reported as published.

Not investment advice.

About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Headquarters
San Diego, Calif.
Employees
2,500
Listed
May 23, 1996
Sector
Health care
Industry
Biological products, (no diagnostic substances)

neurocrine.com, the company’s website

In WallStreetDigest editions

No WallStreetDigest article about NBIX is on the site yet.

  • AMGNAmgen Inc
  • GILDGilead Sciences Inc
  • MRNAModerna, Inc. Common Stock
  • RVMDRevolution Medicines, Inc. Common Stock
  • BIIBBiogen Inc. Common Stock
  • EXELExelixis Inc